Literature DB >> 23152298

Upregulation of soluble epoxide hydrolase in proximal tubular cells mediated proteinuria-induced renal damage.

Qian Wang1, Wei Pang, Zhuan Cui, Junbao Shi, Yan Liu, Bo Liu, Yunfeng Zhou, Youfei Guan, Bruce D Hammock, Yue Wang, Yi Zhu.   

Abstract

Epoxyeicosatrienoic acids, hydrolyzed by soluble epoxide hydrolase (sEH), have multiple biological functions, including the regulation of vascular tone, renal tubular transport, and being anti-inflammatory. Inhibitors of sEH have been demonstrated to be antihypertensive and renal protective. To elucidate the role of sEH in glomerulonephritis, we first determined the expression of sEH in human kidney by examining biopsies from 153 patients with a variety of glomerulonephritis, including minimal-change, membranous, and IgA nephropathy. Immunohistochemical staining of frozen kidney biopsy samples revealed sEH preferentially expressed in the renal proximal tubular cells, and its expression increased in all patients with glomerulonephritis. The level of sEH in the cortex was positively correlated with proteinuria and negatively with serum albumin level. To investigate the role of sEH in proteinuria-induced renal damage, we incubated purified urine protein from patients with rat renal proximal tubular epithelial cells in vitro. The level of sEH was elevated, as were monocyte chemoattractant protein 1 and the process of tubular epithelial-to-mesenchymal transition, characterized with increased α-smooth muscle actin (α-SMA) and decreased E-cadherin. These effects were attenuated by administration of a potent sEH inhibitor and mimicked with adenovirus-mediated sEH overexpression. In adriamycin-induced nephropathic mice, sEH inhibitor did not ameliorate proteinuria or level of serum albumin but reduced the long-term elevated serum creatinine level, interstitial inflammation, fibrosis, and α-SMA expression. Thus upregulation of sEH in proximal tubular cells in chronic proteinuric kidney diseases may mediate proteinuria-induced renal damage; sEH inhibition by increasing renal eicosanoid levels could prevent the progression of chronic proteinuric kidney diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23152298      PMCID: PMC3543623          DOI: 10.1152/ajprenal.00129.2012

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  40 in total

Review 1.  Targeting epoxides for organ damage in hypertension.

Authors:  John D Imig
Journal:  J Cardiovasc Pharmacol       Date:  2010-10       Impact factor: 3.105

2.  An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension.

Authors:  John D Imig; Xueying Zhao; Constantine Z Zaharis; Jeffrey J Olearczyk; David M Pollock; John W Newman; In-Hae Kim; Takaho Watanabe; Bruce D Hammock
Journal:  Hypertension       Date:  2005-09-12       Impact factor: 10.190

Review 3.  Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases.

Authors:  John D Imig
Journal:  Am J Physiol Renal Physiol       Date:  2005-09

4.  Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive rats.

Authors:  Maarten P Koeners; Sebastiaan Wesseling; Arzu Ulu; Rocío López Sepúlveda; Christophe Morisseau; Branko Braam; Bruce D Hammock; Jaap A Joles
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-01-25       Impact factor: 4.310

5.  Attenuation of tobacco smoke-induced lung inflammation by treatment with a soluble epoxide hydrolase inhibitor.

Authors:  Kevin R Smith; Kent E Pinkerton; Takaho Watanabe; Theresa L Pedersen; Seung Jin Ma; Bruce D Hammock
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-31       Impact factor: 11.205

6.  Cell-specific subcellular localization of soluble epoxide hydrolase in human tissues.

Authors:  Ahmed E Enayetallah; Richard A French; Michele Barber; David F Grant
Journal:  J Histochem Cytochem       Date:  2005-11-28       Impact factor: 2.479

Review 7.  Beyond vasodilatation: non-vasomotor roles of epoxyeicosatrienoic acids in the cardiovascular system.

Authors:  Brandon T Larsen; William B Campbell; David D Gutterman
Journal:  Trends Pharmacol Sci       Date:  2006-12-05       Impact factor: 14.819

8.  Homocysteine upregulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo.

Authors:  Donghong Zhang; Xina Xie; Yequn Chen; Bruce D Hammock; Wei Kong; Yi Zhu
Journal:  Circ Res       Date:  2012-02-21       Impact factor: 17.367

9.  Genetic variation in soluble epoxide hydrolase (EPHX2) is associated with forearm vasodilator responses in humans.

Authors:  Craig R Lee; Mias Pretorius; Robert N Schuck; Lauranell H Burch; Jackie Bartlett; Scott M Williams; Darryl C Zeldin; Nancy J Brown
Journal:  Hypertension       Date:  2010-11-22       Impact factor: 10.190

10.  Inhibition of soluble epoxide hydrolase attenuates high-fat-diet-induced hepatic steatosis by reduced systemic inflammatory status in mice.

Authors:  Yan Liu; Huaixin Dang; Dan Li; Wei Pang; Bruce D Hammock; Yi Zhu
Journal:  PLoS One       Date:  2012-06-14       Impact factor: 3.240

View more
  12 in total

1.  Oxylipin profiling of human plasma reflects the renal dysfunction in uremic patients.

Authors:  Da-Yong Hu; Ying Luo; Chang-Bin Li; Chun-Yu Zhou; Xin-Hua Li; Ai Peng; Jun-Yan Liu
Journal:  Metabolomics       Date:  2018-08-01       Impact factor: 4.290

2.  Association between microsomal epoxide hydrolase 1 polymorphisms and susceptibility to esophageal cancer: a meta-analysis.

Authors:  Weixin Zhao; Jianfeng Luo; Xuwei Cai
Journal:  Tumour Biol       Date:  2013-05-17

3.  Podocyte-specific soluble epoxide hydrolase deficiency in mice attenuates acute kidney injury.

Authors:  Ahmed Bettaieb; Shinichiro Koike; Samah Chahed; Yi Zhao; Santana Bachaalany; Nader Hashoush; James Graham; Huma Fatima; Peter J Havel; Artiom Gruzdev; Darryl C Zeldin; Bruce D Hammock; Fawaz G Haj
Journal:  FEBS J       Date:  2017-05-29       Impact factor: 5.542

4.  In Silico Development of Combinatorial Therapeutic Approaches Targeting Key Signaling Pathways in Metabolic Syndrome.

Authors:  Maksim Khotimchenko; Nicholas E Brunk; Mark S Hixon; Daniel M Walden; Hypatia Hou; Kaushik Chakravarty; Jyotika Varshney
Journal:  Pharm Res       Date:  2022-03-21       Impact factor: 4.200

5.  Nitro-oleic acid protects against adriamycin-induced nephropathy in mice.

Authors:  Shanshan Liu; Zhanjun Jia; Li Zhou; Ying Liu; Hong Ling; Shu-Feng Zhou; Aihua Zhang; Yaomin Du; Guangju Guan; Tianxin Yang
Journal:  Am J Physiol Renal Physiol       Date:  2013-03-13

Review 6.  Soluble epoxide hydrolase: gene structure, expression and deletion.

Authors:  Todd R Harris; Bruce D Hammock
Journal:  Gene       Date:  2013-05-20       Impact factor: 3.688

7.  Isolation and characterization of a primary proximal tubular epithelial cell model from human kidney by CD10/CD13 double labeling.

Authors:  Cynthia Van der Hauwaert; Grégoire Savary; Viviane Gnemmi; François Glowacki; Nicolas Pottier; Audrey Bouillez; Patrice Maboudou; Laurent Zini; Xavier Leroy; Christelle Cauffiez; Michaël Perrais; Sébastien Aubert
Journal:  PLoS One       Date:  2013-06-14       Impact factor: 3.240

8.  Genetic deletion of soluble epoxide hydrolase attenuates inflammation and fibrosis in experimental obstructive nephropathy.

Authors:  Chin-Wei Chiang; Hsueh-Te Lee; Der-Cherng Tarng; Ko-Lin Kuo; Li-Ching Cheng; Tzong-Shyuan Lee
Journal:  Mediators Inflamm       Date:  2015-01-22       Impact factor: 4.711

9.  Epoxyeicosatrienoic acid activation moderates endothelial mesenchymal transition to reduce obstructive nephropathy.

Authors:  Babu J Padanilam
Journal:  Kidney Res Clin Pract       Date:  2017-12-31

10.  In vitro and in vivo Metabolism of a Potent Inhibitor of Soluble Epoxide Hydrolase, 1-(1-Propionylpiperidin-4-yl)-3-(4-(trifluoromethoxy)phenyl)urea.

Authors:  Debin Wan; Jun Yang; Cindy B McReynolds; Bogdan Barnych; Karen M Wagner; Christophe Morisseau; Sung Hee Hwang; Jia Sun; René Blöcher; Bruce D Hammock
Journal:  Front Pharmacol       Date:  2019-05-08       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.